SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1260Astellas Licenses Regeneron's Velocimmune(R) Technology for Discovering Humascaram(o)uche-3/30/2007
1259<i>There are clear calls from about that time, here at S.I. I wasn't wDewDiligence_on_SI-3/29/2007
1258Evizon, Evizon, Evizon.... at S.I., the molecule was a joke from the beginninscaram(o)uche-3/29/2007
1257Implying that REGN is hiding something bad based on short released data (hypotheMiljenko Zuanic-3/28/2007
1256<i>The REGN drug is also against a clinically validated target, whereas whDewDiligence_on_SI-3/28/2007
1255I don't think it's really fair to compare these results with those of GEBiomaven-3/28/2007
1254Regardless, by not disaggregating the results by trial arm, REGN is letting us kDewDiligence_on_SI-3/28/2007
1253<i>I infer that the disaggregated data may not be impressive in comparisonBiomaven-3/27/2007
1252New (revised) player in AMD: investorshub.comDewDiligence_on_SI-3/27/2007
1251More questions than answers in today’s PR: investorshub.comDewDiligence_on_SI-3/27/2007
1250Troubling is early evidence that 6.0 mg cumulative dose did not significantly diMiljenko Zuanic-3/27/2007
1249The overall results look good (+5.9 letters=+1.18 lines), but it would be nice iDewDiligence_on_SI-3/27/2007
1248Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular scaram(o)uche-3/27/2007
1247Recurrent GBM Phase 2 with VEGF-TRAP.. utm-ext01a.mdacc.tmc.edu It looks likzeta1961-3/13/2007
1246Thanks to you Miljenko..very much looking forward to trap results.. Some bioteczeta1961-2/18/2007
1245Human Epidermal Growth Factor Receptor 2 Regulates Angiopoietin-2 Expression in Miljenko Zuanic-2/16/2007
1244Thankx, Elizabet. Follow-up time is bit too short to draw any conclusion, but iMiljenko Zuanic-2/16/2007
1243ARVO abstracts are out..a non randomized Lucentis v. Avastin for AMD Since visuzeta1961-2/16/2007
1242A little, very little. Yes, randomization with Avastin carry risk of failing (iMiljenko Zuanic-2/14/2007
1241Nothing new in the presentation that we don't know of. But I am excited by tdr.praveen-2/13/2007
1240Very boring presentation. Nothing new? No FOLFOX regime in PIII, no Avastin heaMiljenko Zuanic-2/13/2007
1239Here is a link to the presentation: en.sanofi-aventis.com Slide No's 167-173dr.praveen-2/13/2007
1238VEGF Trap (AVE0005) (agreement with Regeneron) is a new antiangiogenic agent to dr.praveen-2/13/2007
1237Good luck!rkrw-2/12/2007
1236A reminder to listen to SFA webcast: Regeneron Announces VEGF Trap Clinical Upddr.praveen-2/12/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News